Serum Pro-inflammatory Proteins Have Potential Utility as **Biomarkers for NF-kB Targeting Approaches in DMD**

Bista P¹; Walter G²; Vandenborne K³; Lee B², Nichols A¹, Donovan J¹

¹Catabasis Pharmaceuticals, Cambridge USA; ²University of Florida Physiology and Functional Genomics, Gainesville USA; ³University of Florida Health Physical Therapy, Gainesville USA

Introduction

- > Duchenne Muscular Dystrophy (DMD) is a debilitating childhoodonset disease caused by dystrophin gene mutations.^[1] Muscle function is progressively lost in DMD, with a total loss of ambulatory capacity around late adolescence.
- \succ Activation of NF-kB in muscle occurs at an early age, regardless of mutation type, and is believed to be a central driver of inflammation, muscle degeneration and inhibition of muscle regeneration.^[2]

Results

Consistent with an early burden of muscle inflammation and NF-kB activity in DMD, levels of many serum proteins regulated by NF-kB such as TNF, IL-12, and Osteopontin (OPN) were highest in the youngest boys.

catabasis


Patient #30 : Non-DMD

10

(Median)

9.1

6.8




- \succ Glucocorticoids, the standard of care in DMD, can suppress inflammation and prolong ambulation, albeit with significant sideeffects.^[3]
- > Magnetic Resonance Imaging (MRI) of leg muscles in young DMD boys can detect the progressive muscle inflammation and its delay with glucocorticoid therapy.^[4]
- > Circulating blood markers that can correlate reliably with the status of NF-kB pathway activation in the muscle would allow efficient measurement of response to therapeutic interventions targeting NF-κB.

Methods

ON TOP OF THE FIGHT FOR A CURE

- \succ We performed an analysis of serum from 49 boys with DMD and 5 healthy controls (aged 4 to 18) across a panel of proteins.
- > This sample set from the ImagingDMD cohort also included 3 boys that were steroid-naïve and longitudinal collections from 3 additional boys with DMD that transitioned into or out of glucocorticoid use (Table 1).
- Serum samples were analyzed using Meso Scale Discovery (MSD) electrochemiluminescent detection system.


Glucocorticoid treatment correlated with a decrease in the levels of these cytokines. However, steroid treatment correlated with elevated levels of MMP-9 and MMP-3.




> Fourteen serum proteins showed a significant correlation with age (<u>Table 2</u>).

Table 1	Sample Attribute	Age (Median)	Age (Range)
	All (n=59 samples)	9.5	4.8-17.6
	DMD on corticosteroids (n=48)	10.3	5.1-17.6
	DMD not on corticosteroids (n=6)	8.4	4.8-10.6
	Unaffected (n=5)	9.0	7.1-9.5

Table 2	Analyte	Correlation with age	Spearman r (p-value)
	MMP-3	Direct	+0.56 (<0.0001)
	IL-12p40	Inverse	-0.48 (0.0001)
	CRP	Inverse	-0.46 (0.0002)
	GM-CSF	Inverse	-0.48 (0.0005)
	TNF-β	Inverse	-0.43 (0.0010)
	PIGF	Direct	+0.41 (0.0012)
	IL-17	Inverse	-0.41 (0.0017)
	ICAM-1	Inverse	-0.40 (0.0019)
	IL-4	Direct	+0.49 (0.0023)
	MMP-1	Direct	+0.34 (0.0084)
	TNF-α	Inverse	-0.32 (0.0124)
	MDC	Inverse	-0.30 (0.0208)
	Osteopontin	Inverse	-0.28 (0.0323)
	IFN-γ	Inverse	-0.26 (0.0448)



Changes in serum proteins were rapidly detected within 2-3 months of glucocorticoid use.



Acknowledgments	References	
We express our deepest gratitude to the boys with DMD and their families who continually share parts of their lives with us.	 Kunkel, LM, et. al., <i>Nature</i> 1986; 322:73-77 Chen, YW, et. al., <i>Neurology</i> 2005; 65:826-834 Fenichel, et. al., <i>Neurology</i> 1991; 14:1874- 	
IMAGING UNIVERSITY of UNIVERSITY ON UNIVERSITY OF UNIVERSITY ON UNIVERSITY ON UNI	4. Arpan, I, et. al., Neurology 2014; 83:974-980, and Willcocks, RJ, et. al., Neuromuscul Disord 2015; 24:393-401	

Conclusions

- \succ In DMD serum, several NF- κ B regulated cytokines showed an early peak and a progressive decline as the boys age.
- \succ These cytokines decreased with glucocorticoid treatment, suggesting a glucocorticoid effect on the regulation of NF-κB mediated inflammation.
- \succ On the other hand, MMP-3 and MMP-9 levels in serum were increased with glucocorticoid treatment, suggesting additional modes of glucocorticoid action.
- \succ The rapidly detectable changes in NF-kB driven proteins in serum suggest potential utility for these circulating proteins as biomarkers in therapeutic approaches targeting NF-κB in DMD.